PYC Therapeutics Limited (AU:PYC) has released an update.
PYC Therapeutics Limited has announced the successful administration of the first dose of their drug candidate VP-001 in a trial for Retinitis Pigmentosa type 11 (RP11), with expectations to provide new safety and efficacy data before year-end. The company’s drug candidate, which is the first to enter human trials for RP11, has shown positive early results and is on track for a registrational trial in 2025, aiming to bring forth the first approved treatment for this rare blinding disease.
For further insights into AU:PYC stock, check out TipRanks’ Stock Analysis page.
